120 related articles for article (PubMed ID: 36582107)
21. The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma.
Thies ED; Tanase K; Maeder U; Luster M; Buck AK; Hänscheid H; Reiners C; Verburg FA
Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2281-90. PubMed ID: 25030619
[TBL] [Abstract][Full Text] [Related]
22. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience.
Perros P
J Endocrinol Invest; 1999; 22(11 Suppl):30-4. PubMed ID: 10727003
[TBL] [Abstract][Full Text] [Related]
23. Predictive Value of Clinical and Pathological Characteristics for Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma: A 16-year Retrospective Study.
Chai J; Zhang R; Zheng W; Zhang G; Jia Q; Tan J; Meng Z; Wang R
Front Endocrinol (Lausanne); 2022; 13():930180. PubMed ID: 35846335
[TBL] [Abstract][Full Text] [Related]
24. Cytogenetic Damage Induced by Radioiodine Therapy: A Follow-Up Case Study.
Khvostunov IK; Nasonova E; Krylov V; Rodichev A; Kochetova T; Shepel N; Korovchuk O; Kutsalo P; Shegai P; Kaprin A
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982202
[TBL] [Abstract][Full Text] [Related]
25. Differentiated thyroid carcinoma: Incremental diagnostic value of
Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
[TBL] [Abstract][Full Text] [Related]
26. Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?
Kobe C; Eschner W; Sudbrock F; Weber I; Marx K; Dietlein M; Schicha H
Nuklearmedizin; 2008; 47(1):13-7. PubMed ID: 18278207
[TBL] [Abstract][Full Text] [Related]
27. Fractionated dosage of radioiodine for the ablation of differentiated thyroid carcinoma.
Czepczyński R; Ziemnicka K; Baczyk M; Oleksa R; Ruchała M; Sowiński J
Thyroid; 2005 Nov; 15(11):1261-5. PubMed ID: 16356090
[TBL] [Abstract][Full Text] [Related]
28. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies.
Hartung-Knemeyer V; Nagarajah J; Jentzen W; Ruhlmann M; Freudenberg LS; Stahl AR; Bockisch A; Rosenbaum-Krumme SJ
Ann Nucl Med; 2012 Nov; 26(9):723-9. PubMed ID: 22802008
[TBL] [Abstract][Full Text] [Related]
29. The effect of recombinant human thyroid stimulating hormone on sustaining liver and renal function in thyroid cancer patients during radioactive iodine therapy.
Lee SJ; Lee HY; Lee WW; Kim SE
Nucl Med Commun; 2014 Jul; 35(7):727-32. PubMed ID: 24709982
[TBL] [Abstract][Full Text] [Related]
30. [Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2)].
Dietlein M; Dressler J; Farahati J; Grünwald F; Leisner B; Moser E; Reiners C; Schicha H; Schober O;
Nuklearmedizin; 2004 Aug; 43(4):115-20. PubMed ID: 15316577
[TBL] [Abstract][Full Text] [Related]
31. Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
Wierts R; Brans B; Havekes B; Kemerink GJ; Halders SG; Schaper NN; Backes WH; Mottaghy FM; Jentzen W
J Nucl Med; 2016 Jul; 57(7):1027-32. PubMed ID: 26917706
[TBL] [Abstract][Full Text] [Related]
32. In vivo formation of gamma-H2AX and 53BP1 DNA repair foci in blood cells after radioiodine therapy of differentiated thyroid cancer.
Lassmann M; Hänscheid H; Gassen D; Biko J; Meineke V; Reiners C; Scherthan H
J Nucl Med; 2010 Aug; 51(8):1318-25. PubMed ID: 20660387
[TBL] [Abstract][Full Text] [Related]
33. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
34. Lacrimal System Obstruction After Radioiodine Therapy in Differentiated Thyroid Carcinomas: A Prospective Comparative Study.
da Fonseca FL; Yamanaka PK; Kato JM; Matayoshi S
Thyroid; 2016 Dec; 26(12):1761-1767. PubMed ID: 27565021
[TBL] [Abstract][Full Text] [Related]
35. Differentiated thyroid cancer theranostics: radioiodine and beyond.
Choudhury PS; Gupta M
Br J Radiol; 2018 Nov; 91(1091):20180136. PubMed ID: 30260232
[TBL] [Abstract][Full Text] [Related]
36. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
37. Controversies in Radioiodine Treatment of Low- and Intermediate-risk Thyroid Cancer.
Eilsberger F; Verburg FA
Clin Oncol (R Coll Radiol); 2021 Feb; 33(2):68-74. PubMed ID: 33250287
[TBL] [Abstract][Full Text] [Related]
38. Thyroglobulin levels and thyroglobulin/thyrotropin ratio could predict the success of the ablative/therapeutic
Trevizam PG; Tagliarini JV; Castilho EC; de Alencar Marques M; Kiy Y; Mazeto GMFS
Endocr Res; 2017 Feb; 42(1):42-48. PubMed ID: 27144920
[TBL] [Abstract][Full Text] [Related]
39. Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer.
Jentzen W; Schneider E; Freudenberg L; Eising EG; Görges R; Müller SP; Brandau W; Bockisch A
Nucl Med Commun; 2006 Aug; 27(8):669-76. PubMed ID: 16829767
[TBL] [Abstract][Full Text] [Related]
40. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A
J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]